Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Prevention |
RCV000721531 | SCV000852614 | uncertain significance | not provided | 2017-10-20 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002485825 | SCV002789542 | uncertain significance | Central core myopathy; Malignant hyperthermia, susceptibility to, 1; Congenital multicore myopathy with external ophthalmoplegia; Congenital myopathy with fiber type disproportion; King Denborough syndrome | 2021-09-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002535007 | SCV003272514 | uncertain significance | RYR1-related disorder | 2022-08-11 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 1424 of the RYR1 protein (p.Glu1424Lys). This variant is present in population databases (rs543630280, gnomAD 0.01%). This missense change has been observed in individual(s) with clinical features of malignant hyperthermia susceptibility (PMID: 31559918). ClinVar contains an entry for this variant (Variation ID: 590530). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt RYR1 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |